Aurora Board Unanimously Rejects Curaleaf's Hostile Bid, Citing Inadequate Valuation and Regulatory Deficiencies
ACB sits 57% above its 52-week low of $2.56.
Summary
Aurora's board unanimously recommends rejecting Curaleaf's hostile bid, citing a fairness opinion that values Aurora at US$7.03 per share versus the US$4.00 offer, and revealing procedural defects in the bid.
Key Events · M&A and Partnerships · ACB
-
Board Unanimously Rejects Hostile Bid
Aurora's Board, on the unanimous recommendation of its Special Committee, formally recommends shareholders REJECT Curaleaf's US$4.00 per share offer and NOT TENDER their shares.
-
Fairness Opinion Deems Offer Inadequate
Fort Capital Partners delivered a written opinion dated September 1, 2026, concluding the consideration is inadequate from a financial point of view. The bid implies 0.8x CY2026E revenue versus a 1.8x precedent transaction average, implying US$7.03 per share fair value.
-
Procedural Deficiencies Identified
The Circular states Curaleaf's bid period is truncated below the 105-day minimum required by Canadian securities laws and was not properly commenced in Quebec due to missing French-language advertisement.
-
U.S. Shareholders Face Forced Cash Sales
Individual Aurora shareholders in 29 U.S. states, districts, and territories would not receive Curaleaf shares but instead net cash proceeds from forced sales, subject to brokerage commissions, expenses, and withholding.
Analysis · ACB · Life Sciences
Aurora's Board of Directors has formally and unanimously recommended that shareholders reject Curaleaf's unsolicited takeover bid, backed by a fairness opinion from Fort Capital Partners concluding the US$4.00 per share offer is financially inadequate. The Directors' Circular reveals that the bid implies a 0.8x revenue multiple versus a 1.8x average for recent Canadian cannabis transactions, suggesting a fair value of US$7.03 per share — 76% above the offer. The filing also discloses that Curaleaf's bid is procedurally defective: it fails to meet the 105-day minimum period under Canadian securities laws and was not properly commenced in Quebec. Additionally, shareholders in 29 U.S. states would not receive Curaleaf shares but instead forced cash sales with deductions. This is the first formal board response with full valuation analysis and legal objections, materially escalating the takeover defense.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.